Free Trial

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Update

ProShares Ultra Nasdaq Biotechnology logo with background

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) was the target of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 2,200 shares, a drop of 43.6% from the December 15th total of 3,900 shares. Based on an average daily trading volume, of 11,000 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology

A hedge fund recently raised its stake in ProShares Ultra Nasdaq Biotechnology stock. Jane Street Group LLC boosted its stake in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Free Report) by 8.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,803 shares of the exchange traded fund's stock after acquiring an additional 374 shares during the period. Jane Street Group LLC owned 0.35% of ProShares Ultra Nasdaq Biotechnology worth $306,000 at the end of the most recent reporting period.

ProShares Ultra Nasdaq Biotechnology Stock Down 3.9 %

ProShares Ultra Nasdaq Biotechnology stock traded down $1.97 during trading hours on Tuesday, hitting $48.91. The company had a trading volume of 3,540 shares, compared to its average volume of 7,964. ProShares Ultra Nasdaq Biotechnology has a one year low of $47.19 and a one year high of $69.56. The firm has a 50-day moving average of $56.02 and a 200 day moving average of $61.15.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The company also recently disclosed a dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 23rd were issued a $0.3964 dividend. This is a positive change from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.15. The ex-dividend date was Monday, December 23rd.

About ProShares Ultra Nasdaq Biotechnology

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Read More

Should You Invest $1,000 in ProShares Ultra Nasdaq Biotechnology Right Now?

Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.

While ProShares Ultra Nasdaq Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Affordable AI Stocks: 7 Picks Under $50
2025 Natural Gas Comeback: 3 Stocks Poised for Big Gains
Why the Latest Jobs Data Has Wall Street Nervous

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines